MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
5.14
-0.24
-4.46%
Pre Market: 5.10 -0.04 -0.69% 06:58 05/15 EDT
OPEN
5.36
PREV CLOSE
5.38
HIGH
5.42
LOW
5.06
VOLUME
542
TURNOVER
0
52 WEEK HIGH
10.08
52 WEEK LOW
1.100
MARKET CAP
332.54M
P/E (TTM)
-4.0377
1D
5D
1M
3M
1Y
5Y
1D
Immuneering Corporation: Updates Inbound At The End Of The Month
Seeking Alpha · 2d ago
Weekly Report: what happened at IMRX last week (0504-0508)?
Weekly Report · 4d ago
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction?
Barchart · 6d ago
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
TipRanks · 05/07 16:31
Weekly Report: what happened at IMRX last week (0427-0501)?
Weekly Report · 05/04 09:25
Immuneering's Pancreatic Cancer Data Could Finally Answer Whether Survival Translates to Pivotal Trial Momentum
Barchart · 05/01 16:07
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX)
TipRanks · 04/27 10:30
Weekly Report: what happened at IMRX last week (0420-0424)?
Weekly Report · 04/27 09:26
More
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.